Pages that link to "Q42638632"

The following pages link to Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients (Q42638632):

Displaying 21 items.

• Relation between Age-Related Macular Degeneration and Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis. (Q30239095) (← links)
• Choroidal thickness in patients with coronary artery disease (Q33817248) (← links)
• Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis (Q34216036) (← links)
• Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. (Q34627103) (← links)
• Age-Related Macular Degeneration and Incident Stroke: A Systematic Review and Meta-Analysis (Q35845015) (← links)
• Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab (Q36473024) (← links)
• Longitudinal incidence of adverse outcomes of age-related macular degeneration. (Q36753960) (← links)
• The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration (Q37128680) (← links)
• Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice (Q37569547) (← links)
• Role of statins in the development and progression of age-related macular degeneration. (Q37612307) (← links)
• Coronary Artery Disease and Reticular Macular Disease, a Subphenotype of Early Age-Related Macular Degeneration (Q37629672) (← links)
• Clinical safety of ranibizumab in age-related macular degeneration (Q37650580) (← links)
• Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review (Q37816969) (← links)
• Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File (Q37839380) (← links)
• A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab (Q37881960) (← links)
• What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? (Q38170235) (← links)
• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. (Q38210239) (← links)
• Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death (Q39491363) (← links)
• Age-related macular degeneration: a guide for the primary care physician (Q44443572) (← links)
• Six-Year Incidence and Risk Factors of Age-Related Macular Degeneration in Singaporean Indians: The Singapore Indian Eye Study. (Q55259002) (← links)
• [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany] (Q84131143) (← links)